30
Participants
Start Date
December 31, 2025
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2029
Combination of TIL Transfer and low dose IL-2
"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment.~* TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0).~* Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses)."
University Hospital Basel, Basel
University Hospital, Basel, Switzerland
OTHER